CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice naming Capricor Therapeutics; no new disclosure from the company itself. The lawsuit alleges Capricor made misleading statements regarding changes to the statistical analysis plan for its Deramiocel BLA resubmission prior to FDA review.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.